T
---

Under the Pap	Derwork Reduction Act of 1995, no person			Approved for use through 10/31/99. O Patent and Trademark Office: U.S. DEPARTMENT OF	SB/08/ MB 06
	Substitute for form 1449A/PTO	are required to respond	to a collection of information unless it contain	s a valid OMB control number	OOM.
				Complete if Known	
	INFORMATION DIS	SCLOSURE	Application Number	100/506 000	
	STATEMENT BY A	PPLICANT		09/506,988	
101	P close as many sheets as				
/	<u> </u>		Filing Date		
JH 2	8 2000 (2)		First Named Inventor	February 18, 2000	
12	4		Group Art Unit	Jordan J.N. Tang	
Street	1 & of	6	Examiner Name	1014	
& TRAIL			Attorney Docket Number	OMRF 176	
		OTHER ART NO	ON DATENTA		
	Cite Include	name of the author (in	ON PATENT LITERATURE DOCI CAPITAL LETTERS), title of the artic serial, symposium, catalog, etc.), date	JMENTS	
	item (boo	k, magazine, journal, s	serial, symposium, catalog at a	le (when appropriate), title of the	
	BALDWIN et al "Stand	pu	iblisher, city and/or country where pub	page(s), volume-issue number(s),	- 1
mar	2(3):244-9 (1995)	tural basis of drug	resistance for the V82A mutar	page(s), volume-issue number(s), lished It of HIV-1 proteinase," Nat. Struct. Biol.	
MAX I				Not invest proteinase," Nat. Struct. Biol.	T
1	BOGER, "Renin Inhibitors	Dogian of A	<del></del>		
1 1	restricted inhibitors and a	b model for all	tensinogen Transition-state Ana	logs Containing Statine:Conformationally trate," in <u>Aspartic Proteinases and Their</u>	┸
	Inhibitors, (Kostka, V ec	1) on 401 400	und conformation of renin subst Walter de Gruyter:N.Y., 1985.	trate." in Aspartic Proteins	Т
1 1	CARPENTER, et al. "Anti	iretrovisal share	Walter de Gruyter:N.Y., 1985.	Their	-
1 1	AIDS Society-USA Panel	" ./4M// 200/11/2/	for HIV infection in 1998: Upda	ated recommendations of the International	$\perp$
		OAMA 200(1):78	8-86 (1998)	the international	1
11	CARROLL, et al. "Identific	ation of notest in	hihia	_	1
- 11	combinatorial library," Bio	org. Med. Chem. I	hibitors of <i>Plasmodium falcipard</i> Lett. 8(17):2315-20 (1998).	um plasmepsin II from an encoded statine	╀-
<del></del>	CARROLL		2011: 0(17).2315-20 (1998).	should statille	
- 11	CARROLL, et al., "Evaluat	ion of a structure-	based stating quelle di		1
- 11	plasmepsin II and cathepsi	in D," <i>Bioorg. Mea</i>	based statine cyclic diamino an J. Chem. Lett. 8(22):3203-6 (19	nide encoded combinatorial library against	╁┈
	CHEN of all #TI		2011. 0(22).3203-6 (1)	998).	1
- 11	inhibitors in all-lands in the	nsional structure o	f a mutant HIV-1 protesse diam		1
. 11	inhibitors in clinical trials,"	J. Biol. Chem. 27	0(37):21433-6 (1995)	laying cross-resistance to all protease	$\vdash$
	COFFIN. "HIV populati	<del></del>			1
-11	267(5197):483-9 (1905)	ynamics in vivo: ir	mplications for genetic variation	n, pathogenesis, and therapy," Science	1
			2 Tanation	s, pathogenesis, and therapy," Science	
	CONDRA, et al., "Genetic	Corrolates			1
	protease inhibitor," J. Virol.	70/12), 0270	o viral resistance to indinavir, a	human immunodeficiency virus type 1	
			1996).	1 mindrodenciency virus type 1	
/	CONDRA, et al., "In vivo er	nergence of Link 4	variants resistant to multiple p		
	374(6522):569-71 (1995)	Boure of HIA-1	variants resistant to multiple p	rotease inhibitors " Nature	
<del>/</del>					
10	CRAIG, et al., "Antiviral pro	perties of Ro 21 o	2050		
$\nu$	Antiviral Res. 16(4):295-30	5 (1991).	1959, an inhibitor of human imp	nunodeficiency virus (HIV) proteinase,"	
				proteinase,"	
niner's					
iture N	M Sees		Data Ca		
	1		Date Consider	7 Sent 2000	
MINER: Initial	l if mala			I sent low	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached.

Please type a plus sign (+) inside this box $\rightarrow$	[+]	ĺ
	1 1	ı

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**OMRF 176** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Number 09/506,988 TEMENT BY APPLICANT any sheets as necessary) Filing Date February 18, 2000 First Named Inventor Jordan J.N. Tang **Group Art Unit** 1614 Examiner Name Sheet

Attorney Docket Number

		Omity 176	
		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	I IIICUde name of the author (in CARITAL LETTERS) in the control of the author (in CARITAL LETTERS).	
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	ΤŽ
		publisher gib said/s said/s etc.), date, page(s), volume-issue number(s),	•
i		DEBOUCK & METCALF, "Human Immunodeficiency Virus Protease: A target for AIDS therapy," Drug Devel. Res.	
~~~ I		21:1-17 (1990). Drug Devel, Res.	
My			
		DEBOUCK et al. "Human inner al. "	
1 1		DEBOUCK, et al., "Human immunodeficiency virus protease expressed in <i>Escherichia coli</i> exhibits autoprocessing and specific maturation of the gag precursor," <i>Proc. Natl. Acad. Sci. USA</i> 84,9000 2007 (1007)	
-		- 64, 7680, 7680, 36, 03A 64,8903-8907 (1987).	
1 1		DORSEY, et al., "L-735,524; the design of a potent and oxally biggs with Laws	
		DORSEY, et al., "L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor," <i>J. Med. Chem.</i> 37(21):3443-51 (1994).	
		DUNN et al. "Subsite profession !	
- 1 1		DUNN, et al., "Subsite preferences of retroviral proteinases," Methods Enzymol. 241:254-178 (1994).	
1 1	ŀ	(1004).	
<del>-    </del>		EDNAOLITE	
1 1		ERMOLIEFF, et al., "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1	
	l	Biochemistry 36(40):12364-70 (1997).	
1 1	ļ(	GHOSH, et al., "3-tetrahydrofuran and pyran urothopea so high (6)	
	ľ	GHOSH, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity P <sub>2</sub> -ligands for HIV-1 protease inhibitors," <i>J. Med. Chem.</i> 36:292-94 (1993).	
		GHOSH, et al. "An efficient question of the	- 1
	i	GHOSH, et al., "An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease nhibitors," <i>J. Org. Chem.</i> 56:6500-3 (1991)	
<del></del>		PANES ALL.	
	ĺ	GRAVES, "Human immunodeficiency virus proteinase: now, then, what's next?" Adv Exp Med Biol. 306:395-405	
	G	ULNIK, et al., "Kinetic characterization and cross resistant	
11	р	iULNIK, et al., "Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug ressure," <i>Biochemistry</i> 34(29):9282-7 (1995).	
<del></del>		O et al "Rapid turpous of d	
pux	C	O, et al., "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," Nature 373(6510):123-6	$\dashv$
pul	(1	1995). Nature 373(6510):123-6	

Examiner's	
Signature Mean	Date Considered
The second	1 Jent 2000
*EXAMINER: Initial if reference considered, whether or not citation is in a con-	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached.

Please type a plus sign (+) inside this box $\rightarrow$	+	

PTO/S8/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1614

**OMRF 176** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond  Substitute for form 1449A/PTO	to a collection of information values it as a collection	the same of the sa
Substitute for form 1449A/PTO	as a scale of information unless it contains a	valid OMB control number
		Complete if Known
INFORMATION DISCLOSURE	Application Number	09/506,988
O STATEMENT BY APPLICANT		03/300,308
(use as many sheets as necessary)		
180 Z 0 ZDDD 44	Filing Date	February 18, 2000
\a. \&.	First Named Inventor	Jordan J.N. Tang
	Group Art Unit	1614

**Examiner Name Attorney Docket Number** 

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiners	Cite	Include name of the author (in CARITAL LETTERS) the state of the state	
Initials*	No.¹	milbisher (she addresses etc.), date, page(s), volume-issue number(s),	T
lune		DUNN, et al., "Subsite Preferences of Retroviral Proteinases" Methods in Enzymology 241:254-278 (1994).	╫
14.3			1
1		HONG, et al., "Active-site mobility in human immunodeficier-surviv	1
-		HONG, et al., "Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant," <i>Protein Sci.</i> 7(2):300-5 (1998).	
		HONG, et al., "Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases," Biochemistry 35:123-126 (1996)	1
		proteases," Biochemistry 35:123-126 (1996).	
		HOOVER, et al., "Discovery of inhibitors of human residential life."	j
_		HOOVER, et al., "Discovery of inhibitors of human renin with high oral bioavailability," Adv Exp Med Biol. 362:167-80 (1995).	
$\neg \top$		DO, et al., "Kinetic studies of human improved the	
_	ľ	IDO, et al., "Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S," J. Biol. Chem. 266(36):24359-66 (1991).	
		JACOBSEN, et al., "Characterization of human immunity	
	ŀ	JACOBSEN, et al., "Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959," Virology 206(1):527-34 (1995).	
	$\overline{}$	JACOBSEN, et al. "In vivo recistance to a human in a	
	ľ	JACOBSEN, et al., "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, cinetics, and frequencies," <i>J. Infect. Dis.</i> 173(6):1379-87 (1996).	-
	-	EMPF, et al. "ART-538 is a potent inhibite.	
	t	EMPF, et al., "ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral ioavailability in humans," <i>Proc. Natl. Acad. Sci. U S A.</i> 92(7):2484-8 (1995).	
	k	OHI et al. "Active human inventorial of the	
	L	OHL, et al., "Active human immunodeficiency virus protease is required for viral infectivity," <i>Proc. Natl. Acad. Sci.</i> //SA 85(13):4686-90 (1988).	
. 1	L	APATTO, et al., "X-ray analysis of HIV-1 proteiness at 2.7.4	
My	re	APATTO, et al., "X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among etroviral enzymes," <i>Nature</i> 342(6247):299-302 (1989).	

Examiner's Date Considered Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	+

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

4	_

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	a contection of minimization britishs it contains a va	IND OMB control number
	Co	omplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/506,988
(use as many sheets as necessary)	Filing Date	5-1
	First Named Inventor	February 18, 2000
		Jordan J.N. Tang
<b>\</b>	Group Art Unit	1614
Sheet App of 6	Examiner Name	
Sheel of 6	Attorney Docket Number	OMRF 176

Cuamia a de I		OTHER ART NON PATENT LITERATURE DOCUMENTS	_
Examiner's Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when approaches), title of the	
muais	NO.	nem (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s)	ı
$\longrightarrow$		Dublisher, City and/or country where published	ĺ
		LIN, et al., "Effect of point mutations on the kinetics and the inhibition of human immunodations as the state of the stat	_
Me		Relationship to drug resistance," Biochemistry 34:1143-1152 (1995).	1
		MAJER, et al. "Structure hased subsite eggificity and in the subsite eggificity and in the subsite eggification and eggif	
		MAJER, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," Protein Sci. 6(7):1458-66 (1997).	
		MARCINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," J. Biol. Chem. 251(22):7088-94 (1976).	_
		MELLORS, "Closing in on human immunodeficiency virus-1," Nat. Med. 2(3):274-5 (1996).	
		(1996).	
	$\neg$	MOLLA, et al., "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir," <i>Nat. Med.</i>	_
		2(7):760-6 (1996).	
		MULICHAK & WATENPAUGH, "The crystallographic structure of the protease from human immunodeficiency virus	_
	_	type 2 with two synthetic peptidic transition state analog inhibitors," J. Biol. Chem. 268(18):13103-9 (1993).	
		NAVIA, et al., "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," Nature	
		337(6208):615-20 (1989).	
	F	PATICK, et al., "Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human	_
	ľ	mmunodeficiency virus protease," Antimicrob. Agents Chemother. 40(2):292-7 (1996).	
	F	PENG, et al., "Role of human immunodeficiones virus tura 1 15	
	į.	PENG, et al., "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral nfectivity," J. Virol. 63(6):2550-6 (1989).	
2007	F	OORMAN, et al., "A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2,	
RIKE	ļi	inferred from statistical analysis of an extended substrate data base," J. Biol. Chem. 266(22):14554-61 (1991).	

Examiner's	Data Carried III	1
Signature MM amo	Date Considered	HIL
0. 1		100
*EYAMINED: Initial if reference and it	· · · · · · · · · · · · · · · · · · ·	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached.

Please type a plus sign (+) inside this box $\rightarrow$	1	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 demark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond  Substitute for form 1449A/PTO	0.3 collection of information	Approved for use through 10/31/99. OMB 0651-003 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Substitute for form 1449A/PTO	o desirection of information unless it contains a	valid OMB control number
INFORMATION		Complete if Known
INFORMATION DISCLOSURE	Application Number	09/506,988
P ESTATEMENT BY APPLICANT		33,300
6		
1 8 7000 (was as many sheets as necessary)		
	Filing Date	February 18, 2000
\ \\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	First Named Inventor	Jordan J.N. Tang
No. 18	Group Art Unit	1614
Sheew a TRADENE of 6	Examiner Name	
	Attorney Docket Number	OMRF 176
OTHER ART - N	ON PATENT LITERATURE DOCUM	AFNITO

		OMRF 176
		OTHER ART - NON PATENT LITERATURE DOCUMENTS
xaminers	Cite	
Initials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.
		and the state of t
No		publisher, city and/or country where published
1/2/V		RIDKY & LEIS, "Development of drug resistance to HIV-1 protease inhibitors," J. Biol. Chem. 270(50):29621-3
11 1		(1333). S. Bidi. Chem. 270(50):29621-3
1	ı	RIDKY, et al., "Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme substrate." / Rick Charles and the contractions
. 1	- /	between substrate amino acids bound in adjacent enzyme subsites," J. Biol. Chem. 271:4709-4717 (1996).
1	- 1	bodild in adjacent enzyme subsites," J. Biol. Chem. 271:4709-4717 (1906)
1 7		BOCHEFORT "Biological and all in the state of the state o
	l l	ROCHEFORT, "Biological and clinical significance of cathepsin D in breast cancer," Semin. Cancer Biol. 1(2):153-60
1 1	ľ	3000, Seriii. Cancer Biol. 1(2):153-60
1 1	יון	OSE, et al., "Human immunodeficiency virus type 1 virol beat
1 1	t	ROSE, et al., "Human immunodeficiency virus type 1 viral background plays a major role in development of resistance o protease inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 93(4):1648-53 (1996).
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 7	Īŝ	SCHNEIDER & KENT, "Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease," Cell 54(3):363-8 (1988).
1 1	- In	rotease " Coll Edge State activity of a synthetic 99 residue protein corresponding to the
	ľ	1010d36, Cell 54(3):363-8 (1988).
+		Than A L
1 1	b	IMAN, et al., "Processing of the beta-amyloid precursor, Multiple and the beta-amyloid precursor and the beta-amyloid precursor.
1 1	ja:	iMAN, et al., "Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially myloidogenic fragments," J. Biol. Chem. 268(22):16602-9 (1993).
	,	1 - 7 1 0 0 2 0 (1 0 0 0 ).
1 1	s	ZELKE, "Chemistry of Renin Inhibitors," in, <u>Aspartic Proteinases and Their Inhibitors</u> , (Kostka, ed.), pp. 421-441,
1 1	lo	Valter de Gruyter N.V. 1005, in, Aspartic Proteinases and Their Inhibitors (Kostka add as 40)
1 1	- 1	35 didyter.N.1., 1985).
<del>                                     </del>	- <del> </del> -	ANG R LIADTOLOGY
1 1	11	AND & MARTSUCK, "A kinetic model for comparing protectivity processing and in the comparing processing processing and in the comparing processing proc
1 1	lot	ANG & HARTSUCK, "A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential mutant HIV-1 proteases," FEBS Lett. 367(2):112-6 (1995).
		, and the second
	T(	DH, et al., "Is the AIDS virus recombinant?" Nature 316(6023):21-2 (1985).
		vature 316(6023):21-2 (1985).
<b>\</b>		
	- Tr	MASSELLI AND MET
~ W		DMASSELLI, et al., "The complexities of AIDS: An assessment of the HIV protease as a therapeutic target,"  imicaoggi-Chemistry Today 9:6-27 (1991).
. I W. IV. I	Uh	nimicaoggi-Chemistry Today 9:6-27 (1991).
MMM		

Examiner's Signature Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of Translation is attached.

Translation is attached.

Please type a plus sign (+) inside this box $\rightarrow$	[ + ]	

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Reduction Act of 1995, no persons are required to respond	to a collection of information unless it contains a v	alid OMB control number	
•	Substi	tute for form 1449A/PTO	Complete if Known		
		FORMATION DISCLOSURE ATEMENT BY APPLICANT (ustra many sheets as necessary)	Application Number	09/506,988	
/ / 0	_		Filing Date	February 18, 2000	
1   ""	\	TO THE STATE OF TH	First Named Inventor	Jordan J.N. Tang	
1 / 7/2	•	夏)	Group Art Unit	1614	
			Examiner Name		
Sheet	) · · ·	of 6	Attorney Docket Number	OMRF 176	
	ए हा				
			NON PATENT LITERATURE DOCUM		
Examiner's Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		Τ²		
Phy		TONG, et al., "Crystal structure of huma	in immunodeficiency virus (HIV) typ	pe 2 protease in complex with a reduced Acad. Sci. USA 90(18):8387-91 (1993).	
		TOWLER, et al., "Functional characteriza	ntion of the protease of human endo	ogenous retrovirus, K10: can it	

Phy	amide inhibitor and comparison with HIV-1 protease structures," <i>Proc. Natl. Acad. Sci. USA</i> 90(18):8387-91 (1993).
	TOWLER, et al., "Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?" <i>Biochemistry</i> 37(49):17137-44 (1998).
	VACCA, "Design of Tight-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors," Methods in Enzymology 241:311-334 (1994).
	WEI, et al., "Viral dynamics in human immunodeficiency virus type 1 infection," Nature 373(6510):117-22 (1995).
	WEISS, et al., RNA Tumor Viruses, Cold Spring Harbor:NY, 1984.
	WLODAWER & ERICKSON, "Structure-based inhibitors of HIV-1 protease," Annu. Rev. Biochem. 62:543-85 (1993).
My	WLODAWER, et al., "Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease,"  Science 245(4918):616-21 (1989).

F	
Examiner's Signature Modern	Date Considered \ \frac{\lambda_0}{\lambda_0} \lambd
- Williams	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.